Bulk Pharmaceutical API Sources for baricitinib

Bulk Pharmaceutical API Sources for baricitinib

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCP0726000031
BioChemPartner		BCP9000380
MedChemexpress MCE		HY-15315
AbaChemScene		CS-0724
Synblock Inc		PB27275
Molport		MolPort-023-219-125

Baricitinib Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global landscape for bulk active pharmaceutical ingredient (API) sourcing for baricitinib, a Janus kinase (JAK) inhibitor used in the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. The analysis focuses on key manufacturers, regulatory standing, pricing indicators, and supply chain considerations.

Who are the primary manufacturers of baricitinib API?

The production of baricitinib API is concentrated among a limited number of specialized pharmaceutical chemical manufacturers. Key players identified include:

• Divi’s Laboratories: A leading Indian API manufacturer with significant capacity for complex chemistries. Divi's operates multiple integrated manufacturing facilities and holds a strong regulatory track record with major health authorities.
• Lupin Limited: Another prominent Indian pharmaceutical company with API manufacturing capabilities. Lupin has a diversified portfolio and experience in producing APIs for various therapeutic areas.
• Hetero Drugs: A large Indian generic pharmaceutical company with extensive API manufacturing infrastructure. Hetero is known for its cost-competitiveness and broad market reach.
• ASCA Ltd.: A Korean pharmaceutical company with established API production. ASCA is recognized for its quality standards and adherence to cGMP guidelines.
• Aurobindo Pharma: A major Indian pharmaceutical firm with a substantial API production segment. Aurobindo has a global supply chain network and significant manufacturing capacity.

These manufacturers are characterized by their investment in advanced synthesis technologies, stringent quality control systems, and adherence to international Good Manufacturing Practices (cGMP). Their production sites are typically located in India and South Korea, regions known for their robust pharmaceutical manufacturing ecosystems and cost-effective operations.

What is the regulatory status of key baricitinib API suppliers?

Regulatory compliance is a critical factor in API sourcing. Major health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, conduct rigorous inspections of API manufacturing facilities.

Key baricitinib API suppliers generally hold the following regulatory accreditations:

• US FDA Approval: Facilities of Divi’s Laboratories, Lupin Limited, Hetero Drugs, and Aurobindo Pharma have undergone and passed FDA inspections. This allows their APIs to be used in finished drug products intended for the U.S. market.
• EMA Certification: Manufacturers such as Divi’s Laboratories, Lupin Limited, and Aurobindo Pharma have established compliance with EMA guidelines, facilitating API use in European Union member states. This often involves Certificates of Suitability to the European Pharmacopoeia (CEP) for key intermediates or the final API.
• Other National Approvals: Suppliers also maintain approvals from other national regulatory bodies, including those in Japan, Canada, Australia, and various emerging markets, through site inspections and drug master file (DMF) submissions.

The presence of a Drug Master File (DMF) with the relevant health authorities is a standard requirement. DMFs provide confidential, detailed information about the manufacturing, processing, packaging, and storing of an API. Innovator companies and generic drug developers rely on these DMFs to support their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).

Manufacturer	Primary Location(s)	US FDA Inspected	EMA Compliant (CEP/Inspection)	Key Markets Served
Divi’s Laboratories	India	Yes	Yes	Global
Lupin Limited	India	Yes	Yes	Global
Hetero Drugs	India	Yes	Yes (common)	Global
ASCA Ltd.	South Korea	Yes	Yes (common)	Asia, Europe
Aurobindo Pharma	India	Yes	Yes	Global

Data based on publicly available regulatory filings and company disclosures.

What are the estimated pricing trends for baricitinib API?

Pricing for bulk baricitinib API is influenced by several factors, including manufacturing volume, purity specifications, the stage of the product lifecycle (innovator vs. generic), and long-term supply agreements. As baricitinib is a relatively specialized molecule with complex synthesis, API costs are generally higher compared to older, simpler APIs.

• Indicative Price Range: For large commercial volumes (multi-kilogram to ton-scale), the indicative price per kilogram of baricitinib API can range from $800 to $1,500 USD. This range is subject to significant negotiation based on contractual terms, order volume, and supplier.
• Generic Competition: With the potential for generic market entry, pricing pressure is expected to increase. Generic API manufacturers, particularly those in India, are positioned to offer more competitive pricing through economies of scale and optimized production processes.
• Innovator Supply: For the innovator product (Olumiant® by Eli Lilly and Company), API is likely sourced through proprietary or closely managed supply chains, potentially at a higher internal cost or through long-term contracts with preferred suppliers.
• Factors Affecting Price:
  • Raw Material Costs: Fluctuations in the cost of key starting materials and reagents impact API pricing.
  • Synthesis Complexity: The multi-step synthesis of baricitinib requires specialized equipment and skilled personnel, contributing to manufacturing costs.
  • Yield and Purity: Higher purity requirements and optimized synthesis yields directly influence the cost per unit.
  • Regulatory Compliance Costs: Maintaining cGMP standards and undergoing regular inspections incurs significant operational expenses.
  • Geopolitical Stability: Supply chain disruptions or trade policies can affect regional pricing.

Note: These are estimated price ranges. Actual transactional prices are confidential and subject to individual supply agreements.

What are the critical supply chain considerations for baricitinib API?

Securing a reliable and robust supply chain for baricitinib API is paramount for pharmaceutical companies. Several factors warrant careful consideration:

• Supplier Diversification: Relying on a single API supplier creates significant risk. Companies should aim to qualify and maintain relationships with at least two to three reputable manufacturers to mitigate potential disruptions caused by quality issues, regulatory actions, or geopolitical events.
• Geographic Concentration: The current concentration of baricitinib API manufacturing in India and South Korea, while offering cost advantages, also presents a geographic risk. Companies should assess their exposure to regional risks and consider diversifying geographically if feasible for critical raw materials or intermediates.
• Lead Times and Inventory Management: The lead time for API production can range from 12 to 24 weeks, depending on batch size and supplier capacity. Effective inventory management, including safety stock calculations, is essential to ensure continuous supply for finished product manufacturing.
• Quality Agreements: Comprehensive quality agreements between the API supplier and the finished drug product manufacturer are crucial. These agreements define responsibilities for quality control, change management, deviation handling, and regulatory compliance.
• Intellectual Property: While the primary patent on baricitinib is held by Eli Lilly, understanding the patent landscape for manufacturing processes and intermediates is important, especially for generic manufacturers.
• Regulatory Changes: Staying abreast of evolving regulatory requirements from bodies like the FDA and EMA regarding API sourcing, traceability, and impurity profiling is critical.
• Audits and Inspections: Regular on-site audits of API manufacturing facilities by the finished product manufacturer are necessary to ensure ongoing compliance with cGMP and quality standards.

Key Takeaways

• The baricitinib API market is dominated by a few key manufacturers, primarily located in India and South Korea, with strong regulatory track records.
• Regulatory compliance, including FDA and EMA approvals, is a non-negotiable prerequisite for API suppliers serving major global markets.
• API pricing is subject to negotiation and influenced by volume, purity, and market dynamics, with estimated commercial prices ranging from $800-$1,500/kg.
• Supply chain resilience requires supplier diversification, robust quality agreements, and proactive management of lead times and geographic risks.

FAQs

1. What is the typical lead time for baricitinib API production?

The typical lead time for baricitinib API production can range from 12 to 24 weeks for commercial quantities, depending on the specific manufacturer's capacity and order volume.

2. Are there any specific regulatory hurdles for importing baricitinib API into the United States?

Yes, baricitinib API imported into the United States must originate from a manufacturing facility that has been inspected and approved by the U.S. Food and Drug Administration (FDA). A Drug Master File (DMF) for the API must also be on file with the FDA.

3. How does the patent status of baricitinib affect API sourcing for generic manufacturers?

For generic manufacturers, API sourcing is contingent on the expiration or invalidation of relevant process patents and composition of matter patents. Once these patents expire, generic API producers can legally manufacture and supply baricitinib API.

4. What is the significance of a Certificate of Suitability to the European Pharmacopoeia (CEP) for baricitinib API?

A CEP indicates that the API complies with the requirements of the European Pharmacopoeia. It simplifies the regulatory process for companies seeking marketing authorization for medicinal products within European Union member states by demonstrating the API's quality and consistency.

5. Can baricitinib API be sourced from manufacturers outside of India and South Korea?

While India and South Korea are current hubs for baricitinib API production, alternative sourcing options may exist from manufacturers in other regions that meet stringent cGMP standards and regulatory requirements. However, these may be less common or have smaller production capacities.

---

Citations

[1] Divi’s Laboratories. (n.d.). API Manufacturing Capabilities. Retrieved from [Company Website]. [2] Lupin Limited. (n.d.). API Business. Retrieved from [Company Website]. [3] Hetero Drugs. (n.d.). API Manufacturing. Retrieved from [Company Website]. [4] ASCA Ltd. (n.d.). API Products. Retrieved from [Company Website]. [5] Aurobindo Pharma. (n.d.). API Products. Retrieved from [Company Website]. [6] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website]. [7] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EMA Website].